200 related articles for article (PubMed ID: 18383890)
1. Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer.
Lumachi F; Ermani M; Marino F; Di Cristofaro L; Tombolan V; Brunello A; Roma A; Basso U
Anticancer Res; 2008; 28(1B):491-3. PubMed ID: 18383890
[TBL] [Abstract][Full Text] [Related]
2. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
3. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
4. [Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].
Calzada L; Salazar EL; Pedron Nuevo N
Ginecol Obstet Mex; 1996 Mar; 64():135-9. PubMed ID: 8729191
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
6. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
7. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.
Jalava P; Kuopio T; Huovinen R; Laine J; Collan Y
Anticancer Res; 2005; 25(3c):2535-42. PubMed ID: 16080489
[TBL] [Abstract][Full Text] [Related]
9. [Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].
Zhao J; Wu YL; Wang YD; Zhao GR; Wang J
Di Yi Jun Yi Da Xue Xue Bao; 2004 Dec; 24(12):1437-9. PubMed ID: 15604081
[TBL] [Abstract][Full Text] [Related]
10. Estrogen and progesterone receptor status in breast cancer: effect of oral contraceptive pills and hormone replacement therapy.
Tewari M; Pradhan S; Singh U; Shukla HS
Breast; 2007 Oct; 16(5):540-5. PubMed ID: 17587581
[TBL] [Abstract][Full Text] [Related]
11. Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast.
Lebrecht A; Buchmann J; Hefler L; Lampe D; Koelbl H
Anticancer Res; 2002; 22(3):1909-11. PubMed ID: 12168892
[TBL] [Abstract][Full Text] [Related]
12. Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.
Olsson H; Lindahl B; Ranstam J; Borg A; Fernö M; Norgren A
Anticancer Res; 1987; 7(4B):853-6. PubMed ID: 3674773
[TBL] [Abstract][Full Text] [Related]
13. Expression of estrogen receptor alpha and progesterone receptor in normal human breast epithelium.
Umekita Y; Souda M; Ohi Y; Rai Y; Sagara Y; Sagara Y; Yoshida H
In Vivo; 2007; 21(3):535-9. PubMed ID: 17591366
[TBL] [Abstract][Full Text] [Related]
14. A French national survey on infiltrating breast cancer: analysis of clinico-pathological features and treatment modalities in 1159 patients.
Cutuli B; Cottu PH; Guastalla JP; Mechin H; Costa A; Jourdan R
Breast Cancer Res Treat; 2006 Jan; 95(1):55-64. PubMed ID: 16261401
[TBL] [Abstract][Full Text] [Related]
15. [Expression of ER, PR and cyclin D1 in breast infiltrating ductal carcinoma and their clinicopathological significance].
Wang ZB; Zhao P; Liu M; Li XH
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):514-7. PubMed ID: 15949328
[TBL] [Abstract][Full Text] [Related]
16. [Accuracy of conservative treatment for infiltrating lobular breast cancer: a retrospective study of 217 infiltrating lobular carcinomas and 2155 infiltrating ductal carcinomas].
Paumier A; Sagan C; Campion L; Fiche M; Andrieux N; Dravet F; Pioud R; Classe JM
J Gynecol Obstet Biol Reprod (Paris); 2003 Oct; 32(6):529-34. PubMed ID: 14593298
[TBL] [Abstract][Full Text] [Related]
17. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
18. Association of surgery with improved survival in stage IV breast cancer patients.
Blanchard DK; Shetty PB; Hilsenbeck SG; Elledge RM
Ann Surg; 2008 May; 247(5):732-8. PubMed ID: 18438108
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms.
Kravchenko J; Akushevich I; Seewaldt VL; Abernethy AP; Lyerly HK
Breast Cancer Res Treat; 2011 Jul; 128(2):483-93. PubMed ID: 21225455
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for initial lung metastasis from breast invasive ductal carcinoma in stages I-III of operable patients.
Gao D; Du J; Cong L; Liu Q
Jpn J Clin Oncol; 2009 Feb; 39(2):97-104. PubMed ID: 19052036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
